In patients with ulcerative colitis in remission, vitamin D3 injection raised the mean fold change of the body's own hCAP18 (LL‑37) gene expression more than placebo.
In plain wordsIn people with ulcerative colitis, vitamin D raised the body's own LL‑37 gene activity more than placebo.
- Peptide
- LL-37
- Outcome
- IncreasehCAP18/LL-37 gene expression fold change
- Study
n = 90
- Comparator
- Placebo (normal saline)
- Outcome group
- Immune response · Immune and inflammation
Measurements
- Mean fold change in hCAP18 expression
- 3.13 fold
- vitamin D group
- Mean fold change in hCAP18 expression
- 1.09 fold
- placebo group
Source sentences
The mean fold change in hCAP18 gene expression in Vitamin D group was significantly higher than placebo group.
3 context sentences(design, population, supporting numbers)
(Mean ± SD: 3.13 ± 2.56 vs 1.09 ± 0.56; median ± interquartile range: 2.17 ± 3.81 vs 0.87 ± 0.53, P< 0.001).
To characterize the effects of Vitamin D on cathelicidin (hCAP/LL37) gene expression, ESR, and serum hs-CRP levels.
Ninety UC patients on remission were randomized to receive 300,000 IU intramuscular Vitamin D or 1 mL normal saline as placebo, respectively.
This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.